Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Liver Cirrhosis

  Free Subscription


Articles published in Hepatology

Retrieve available abstracts of 198 articles:
HTML format



Single Articles


    October 2021
  1. MANCUSO A
    Portal vein thrombosis in cirrhosis: the issue of treatment.
    Hepatology. 2021 Oct 28. doi: 10.1002/hep.32216.
    PubMed     Abstract available


  2. SANYAL AJ, Anstee QM, Trauner M, Lawitz EJ, et al
    Cirrhosis Regression is Associated with Improved Clinical Outcomes in Patients with Nonalcoholic Steatohepatitis.
    Hepatology. 2021 Oct 18. doi: 10.1002/hep.32204.
    PubMed     Abstract available


  3. SINGAL AG, Nabihah T, Mehta A, Marrero JA, et al
    GALAD Demonstrates High Sensitivity for HCC Surveillance in a Cohort of Patients with Cirrhosis.
    Hepatology. 2021 Oct 7. doi: 10.1002/hep.32185.
    PubMed     Abstract available


    September 2021
  4. GARCIA-TSAO G
    Can we rely on changes in HVPG in patients with cirrhosis?
    Hepatology. 2021 Sep 27. doi: 10.1002/hep.32159.
    PubMed     Abstract available


  5. DRIEVER EG, von Meijenfeldt FA, Adelmeijer J, de Haas RJ, et al
    Non-malignant portal vein thrombi in patients with cirrhosis consist of intimal fibrosis with or without a fibrin-rich thrombus.
    Hepatology. 2021 Sep 24. doi: 10.1002/hep.32169.
    PubMed     Abstract available


  6. WANG S, Whitlock R, Xu C, Taneja S, et al
    Frailty is associated with increased risk of cirrhosis disease progression and death.
    Hepatology. 2021 Sep 15. doi: 10.1002/hep.32157.
    PubMed     Abstract available


  7. RAEVENS S, Boret M, De Pauw M, Fallon MB, et al
    Pulmonary Abnormalities in Liver Disease: Relevance to Transplantation and Outcome.
    Hepatology. 2021;74:1674-1686.
    PubMed     Abstract available


    August 2021
  8. INNES H, Crooks CJ, Aspinall E, Card TR, et al
    Characterising the risk interplay between alcohol intake and body mass index on cirrhosis morbidity.
    Hepatology. 2021 Aug 28. doi: 10.1002/hep.32123.
    PubMed     Abstract available


  9. ALLAIRE M, Garcia-Pagan JC, Walter A, Bureau C, et al
    Salvage TIPS in cirrhotic patients with variceal bleeding: MELD, lactates and << a la carte >> decision.
    Hepatology. 2021 Aug 5. doi: 10.1002/hep.32091.
    PubMed     Abstract available


  10. BOSCH J, Chung C, Carrasco-Zevallos OM, Harrison SA, et al
    A Machine Learning Approach to Liver Histological Evaluation Predicts Clinically Significant Portal Hypertension in NASH Cirrhosis.
    Hepatology. 2021 Aug 1. doi: 10.1002/hep.32087.
    PubMed     Abstract available


  11. SAVIANO A, Wrensch F, Ghany MG, Baumert TF, et al
    Liver Disease and Coronavirus Disease 2019: From Pathogenesis to Clinical Care.
    Hepatology. 2021;74:1088-1100.
    PubMed     Abstract available


    July 2021
  12. PIANO S, Cardenas A
    Metabolomics to predict acute kidney injury in cirrhosis.
    Hepatology. 2021 Jul 16. doi: 10.1002/hep.32060.
    PubMed     Abstract available


  13. LAI JC, Tandon P, Bernal W, Tapper EB, et al
    Malnutrition, Frailty, and Sarcopenia in Patients With Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases.
    Hepatology. 2021 Jul 7. doi: 10.1002/hep.32049.
    PubMed     Abstract available


  14. CAPORALI C, Turco L, Prampolini F, Quaretti P, et al
    Proximal splenic artery embolization to treat refractory ascites in a cirrhotic patient.
    Hepatology. 2021 Jul 4. doi: 10.1002/hep.32037.
    PubMed     Abstract available


    June 2021
  15. FLEMMING JA, Djerboua M, Groome PA, Booth CM, et al
    NAFLD and alcohol-related liver disease will be responsible for almost all new diagnoses of cirrhosis in Canada by 2040.
    Hepatology. 2021 Jun 26. doi: 10.1002/hep.32032.
    PubMed     Abstract available


  16. LIU H, Lee SS
    Diagnostic criteria of cirrhotic cardiomyopathy: out with the old, in with the new?
    Hepatology. 2021 Jun 21. doi: 10.1002/hep.32021.
    PubMed     Abstract available


  17. JEPSEN P, Tapper EB, Deleuran T, Kazankov K, et al
    Risk and outcome of venous and arterial thrombosis in patients with cirrhosis: a Danish nationwide cohort study.
    Hepatology. 2021 Jun 16. doi: 10.1002/hep.32019.
    PubMed     Abstract available


  18. SHI YF, Xie WZ
    Letter to the Editor: Risk Stratification in Patients With Child-Pugh B Cirrhosis and Acute Variceal Bleeding.
    Hepatology. 2021 Jun 15. doi: 10.1002/hep.32013.
    PubMed     Abstract available


  19. MAZUMDER NR, Simpson D, Atiemo K, Jackson K, et al
    Black Patients With Cirrhosis Have Higher Mortality and Lower Transplant Rates: Results From a Metropolitan Cohort Study.
    Hepatology. 2021 Jun 15. doi: 10.1002/hep.31742.
    PubMed     Abstract available


  20. JINDAL A, Sharma S
    Biomarkers for predicting renal outcomes in decompensated cirrhosis - Need a closer look!
    Hepatology. 2021 Jun 9. doi: 10.1002/hep.32005.
    PubMed     Abstract available


    May 2021
  21. SUN LY, Hu JY, Liang L, Tong XM, et al
    Letter to the Editor: Is Male Gender Associated with Increased Liver-related Mortality in Primary Biliary Cholangitis and Cirrhosis?
    Hepatology. 2021 May 22. doi: 10.1002/hep.31916.
    PubMed     Abstract available


  22. JOHN BV, Deng Y, Martin P, Levy C, et al
    Response to "Is Male Gender Associated with Increased Liver-related Mortality in Primary Biliary Cholangitis and Cirrhosis?"
    Hepatology. 2021 May 22. doi: 10.1002/hep.31917.
    PubMed     Abstract available


  23. MEHTA G, Jalan R
    The 'Alter Ego' of Albumin in Cirrhosis.
    Hepatology. 2021 May 18. doi: 10.1002/hep.31908.
    PubMed     Abstract available


  24. BAJAJ JS, Garcia-Tsao G, Reddy KR, O'Leary JG, et al
    Admission urinary and serum metabolites predict renal outcomes in hospitalized patients with cirrhosis.
    Hepatology. 2021 May 18. doi: 10.1002/hep.31907.
    PubMed     Abstract available


  25. VALSAN A, Verma N, Singh V
    Non-invasive differentiation of porto-sinusoidal vascular disease and cirrhosis: The Devil is in the details!
    Hepatology. 2021 May 11. doi: 10.1002/hep.31896.
    PubMed     Abstract available


  26. ELKRIEF L, Lazareth M, Rautou PE
    Reply to: "Non-invasive differentiation of porto-sinusoidal vascular disease and cirrhosis: The Devil is in the details!"
    Hepatology. 2021 May 11. doi: 10.1002/hep.31894.
    PubMed     Abstract available


    April 2021
  27. SONG Z, Chen W, Athavale D, Ge X, et al
    Osteopontin Takes Center Stage in Chronic Liver Disease.
    Hepatology. 2021;73:1594-1608.
    PubMed     Abstract available


  28. CHEN L, Guo P, Li W, Fang F, et al
    Perturbation of Specific Signaling Pathways Is Involved in Initiation of Mouse Liver Fibrosis.
    Hepatology. 2021;73:1551-1569.
    PubMed     Abstract available


    March 2021
  29. YASUDO H, Ando T, Maehara A, Ando T, et al
    A possible association between a novel NLRP1 mutation and an autoinflammatory disease involving liver cirrhosis.
    Hepatology. 2021 Mar 19. doi: 10.1002/hep.31818.
    PubMed     Abstract available


  30. BALDASSARRE M, Naldi M, Zaccherini G, Bartoletti M, et al
    Determination of effective albumin in patients with decompensated cirrhosis: clinical and prognostic implications.
    Hepatology. 2021 Mar 12. doi: 10.1002/hep.31798.
    PubMed     Abstract available


  31. PONZIANI FR, Gasbarrini A, Pompili M
    Letter to the Editor. Restructuring the Gut Microbiota of Cirrhotic Patients after HCV Eradication: a Matter of Time?
    Hepatology. 2021 Mar 5. doi: 10.1002/hep.31784.
    PubMed     Abstract available


    February 2021
  32. JOHN BV, Aitcheson G, Schwartz KB, Shabbir Khakoo N, et al
    Male Gender is Associated with Higher Rates of Liver-related Mortality in Primary Biliary Cholangitis and Cirrhosis.
    Hepatology. 2021 Feb 26. doi: 10.1002/hep.31776.
    PubMed     Abstract available


  33. HUANG DQ, Yeo YH, Nguyen MH
    Letter to the Editor: HCC surveillance in cirrhosis patients: Is the real-world situation even worse than reported?
    Hepatology. 2021 Feb 22. doi: 10.1002/hep.31760.
    PubMed     Abstract available


  34. RICH NE, Parikh ND, Singal AG
    HCC Surveillance in Cirrhosis Patients: Room for Improvement.
    Hepatology. 2021 Feb 22. doi: 10.1002/hep.31762.
    PubMed     Abstract available


  35. SANSOE G, Aragno M, Wong F
    Covid-19 and liver cirrhosis: focus on the non-classical renin-angiotensin system and implications for therapy.
    Hepatology. 2021 Feb 1. doi: 10.1002/hep.31728.
    PubMed     Abstract available


  36. PIROLA CJ, Sookoian S
    NAFLD and Cardiometabolic Risk Factors: The Liver Fibrosis Trajectory Through the Lens of Biological Interactions.
    Hepatology. 2021;73:479-482.
    PubMed    


    January 2021
  37. CARACENI P, Vargas V, Sola E, Alessandria C, et al
    The use of Rifaximin in Patients with Cirrhosis.
    Hepatology. 2021 Jan 9. doi: 10.1002/hep.31708.
    PubMed     Abstract available


  38. WELLHONER F, Doscher N, Woelfl F, Vital M, et al
    Eradication of chronic HCV infection: improvement of dysbiosis only in patients without liver cirrhosis.
    Hepatology. 2021 Jan 7. doi: 10.1002/hep.31700.
    PubMed     Abstract available


  39. NORTHUP PG, Garcia-Pagan JC, Garcia-Tsao G, Intagliata NM, et al
    Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases.
    Hepatology. 2021;73:366-413.
    PubMed    


    December 2020
  40. KEISHAM A, Taneja S, Roy A, Singh V, et al
    ABIDE in NAFLD: A potential game changer in a select cohort of cirrhosis.
    Hepatology. 2020 Dec 4. doi: 10.1002/hep.31667.
    PubMed     Abstract available


  41. ANAND A, Pathak P, Shalimar
    Letter to the editor: ABIDE model for predicting decompensation in non-alcoholic fatty liver disease-related cirrhosis.
    Hepatology. 2020 Dec 3. doi: 10.1002/hep.31668.
    PubMed     Abstract available


  42. SELCK TJ, Bok J, Amintavakoli R
    Letter to the Editor: Do Weather and Sunlight Really Affect Alcohol Consumption?
    Hepatology. 2020;72:2239.
    PubMed    


  43. VENTURA-COTS M, Abraldes JG, Bataller R
    Reply.
    Hepatology. 2020;72:2239-2240.
    PubMed    


    November 2020
  44. SIMON TG, Chan AT, Huttenhower C
    Microbiome Biomarkers: One Step Closer in NAFLD-Cirrhosis.
    Hepatology. 2020 Nov 29. doi: 10.1002/hep.31660.
    PubMed     Abstract available


  45. SIMONETTO DA, Shah VH, Kamath PS
    Surgery in patients with cirrhosis: as much an art as science.
    Hepatology. 2020 Nov 21. doi: 10.1002/hep.31643.
    PubMed     Abstract available


  46. IOANNOU GN, Liang PS, Locke E, Green P, et al
    Cirrhosis and SARS-CoV-2 infection in US Veterans: risk of infection, hospitalization, ventilation and mortality.
    Hepatology. 2020 Nov 21. doi: 10.1002/hep.31649.
    PubMed     Abstract available


  47. SETIAWAN VW, Rosen HR
    Stratification of residual risk of hepatocellular carcinoma following HCV clearance with DAA in patients with advanced fibrosis and cirrhosis.
    Hepatology. 2020 Nov 18. doi: 10.1002/hep.31639.
    PubMed     Abstract available


  48. KOKUDO T
    Evaluating Liver Function in Patients With Cirrhosis.
    Hepatology. 2020 Nov 13. doi: 10.1002/hep.31626.
    PubMed     Abstract available


  49. LOOMBA R, Noureddin M, Kowdley KV, Kohli A, et al
    Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis due to NASH.
    Hepatology. 2020 Nov 10. doi: 10.1002/hep.31622.
    PubMed     Abstract available


  50. BANINI BA, P Kumar D, Cazanave S, Seneshaw M, et al
    Identification of a metabolic, transcriptomic and molecular signature of PNPLA3-mediated acceleration of steatohepatitis.
    Hepatology. 2020 Nov 1. doi: 10.1002/hep.31609.
    PubMed     Abstract available


    October 2020
  51. LONG MT, Zhang X, Xu H, Liu CT, et al
    Hepatic fibrosis associates with multiple cardiometabolic disease risk factors: The Framingham Heart Study.
    Hepatology. 2020 Oct 30. doi: 10.1002/hep.31608.
    PubMed     Abstract available


  52. BROWN SA, Izzy M, Watt KD
    Pharmacotherapy for Weight Loss in Cirrhosis and Liver Transplantation: Translating the Data and Underutilized Potential.
    Hepatology. 2020 Oct 12. doi: 10.1002/hep.31595.
    PubMed     Abstract available


  53. ALONSO S, Manzano ML, Gea F, Gutierrez ML, et al
    A model based on non-invasive markers predicts very low hepatocellular carcinoma risk after viral response in HCV-advanced fibrosis.
    Hepatology. 2020 Oct 6. doi: 10.1002/hep.31588.
    PubMed     Abstract available


  54. LA MURA V, Villanueva C, Abraldes JG, Bosch J, et al
    Reply.
    Hepatology. 2020;72:1494-1495.
    PubMed    


  55. KUNZMANN LK, Schoknecht T, Poch T, Henze L, et al
    Monocytes as Potential Mediators of Pathogen-Induced T-Helper 17 Differentiation in Patients With Primary Sclerosing Cholangitis (PSC).
    Hepatology. 2020;72:1310-1326.
    PubMed     Abstract available


    September 2020
  56. CALZADILLA-BERTOT L, Vilar-Gomez E, Wong VW, Romero-Gomez M, et al
    ABIDE: an accurate predictive model of liver decompensation in patients with non-alcoholic fatty liver-related cirrhosis.
    Hepatology. 2020 Sep 25. doi: 10.1002/hep.31576.
    PubMed     Abstract available


  57. MAHMUD N, Fricker Z, Hubbard RA, Ioannou GN, et al
    Novel Risk Prediction Models for Post-Operative Mortality in Patients with Cirrhosis.
    Hepatology. 2020 Sep 16. doi: 10.1002/hep.31558.
    PubMed     Abstract available


  58. MARTIN N, Ziegler DV, Parent R, Bernard D, et al
    Hepatic Stellate Cell Senescence in Liver Tumorigenesis.
    Hepatology. 2020 Sep 15. doi: 10.1002/hep.31556.
    PubMed     Abstract available


  59. THOMSON MJ, Lok AS, Tapper EB
    Appropriate and Potentially Inappropriate Medication Use in Decompensated Cirrhosis.
    Hepatology. 2020 Sep 10. doi: 10.1002/hep.31548.
    PubMed     Abstract available


  60. KUMAR M
    Reply.
    Hepatology. 2020;72:1160.
    PubMed    


    August 2020
  61. SCHWANTES-AN TH, Darlay R, Mathurin P, Masson S, et al
    Genome-wide association study and meta-analysis on alcohol-related liver cirrhosis identifies novel genetic risk factors.
    Hepatology. 2020 Aug 27. doi: 10.1002/hep.31535.
    PubMed     Abstract available


  62. LEUNG KK, James PD, Jaberi A, Hirschfield GM, et al
    Esophageal Stenting as Bridge Therapy to Direct Intrahepatic Portocaval Shunt for Refractory Variceal Bleeding.
    Hepatology. 2020 Aug 11. doi: 10.1002/hep.31519.
    PubMed     Abstract available


  63. KULKARNI AV, Sharma M, Kumar P, Gupta R, et al
    Midodrine for Hepatic Hydrothorax.
    Hepatology. 2020 Aug 8. doi: 10.1002/hep.31513.
    PubMed     Abstract available


  64. DEGASPERI E, Galmozzi E, Pelusi S, D'Ambrosio R, et al
    Hepatic fat - genetic risk score predicts hepatocellular carcinoma in HCV cirrhotic patients treated with DAAs.
    Hepatology. 2020 Aug 6. doi: 10.1002/hep.31500.
    PubMed     Abstract available


  65. GINDIN Y, Chung C, Jiang Z, Zhou JZ, et al
    A Fibrosis-Independent Hepatic Transcriptomic Signature Identifies Novel Drivers of Disease Progression in Primary Sclerosing Cholangitis.
    Hepatology. 2020 Aug 3. doi: 10.1002/hep.31488.
    PubMed     Abstract available


  66. WEN Y, Ju C
    MER Proto-Oncogene Tyrosine Kinase: A Novel Potential Target to Treat Nonalcoholic Steatohepatitis Fibrosis.
    Hepatology. 2020;72:772-774.
    PubMed    


    July 2020
  67. LV Y, Wang Z, Li K, Wang Q, et al
    Risk Stratification based on CLIF Consortium Acute Decompensation score in Patients with Child-Pugh B Cirrhosis and Acute Variceal Bleeding.
    Hepatology. 2020 Jul 24. doi: 10.1002/hep.31478.
    PubMed     Abstract available


  68. SCHULTHEISS C, Simnica D, Willscher E, Oberle A, et al
    Next-generation immunosequencing reveals pathological T cell architecture in autoimmune hepatitis.
    Hepatology. 2020 Jul 21. doi: 10.1002/hep.31473.
    PubMed     Abstract available


  69. JIANG L, Lang S, Duan Y, Zhang X, et al
    Intestinal virome in patients with alcoholic hepatitis.
    Hepatology. 2020 Jul 12. doi: 10.1002/hep.31459.
    PubMed     Abstract available


  70. THAN NN, Cataluna JG, Majumdar A
    Acute confusion post liver transplantation: HE or not HE, that is the question.
    Hepatology. 2020 Jul 6. doi: 10.1002/hep.31452.
    PubMed     Abstract available


  71. LISMAN T
    Hemostatic Changes of Acute Kidney Injury in Patients With Cirrhosis: What Do They Mean?
    Hepatology. 2020 Jul 4. doi: 10.1002/hep.31451.
    PubMed     Abstract available


  72. ZANETTO A, Rinder HM, Campello E, Saggiorato G, et al
    Acute kidney injury in decompensated cirrhosis is associated with both hypo- and hyper-coagulable features.
    Hepatology. 2020 Jul 2. doi: 10.1002/hep.31443.
    PubMed     Abstract available


  73. SU T, Iwakiri Y
    Endothelial Leukocyte Cell-Derived Chemotaxin 2/Tyrosine Kinase With Immunoglobulin-Like and Epidermal Growth Factor-Like Domains 1 Signaling in Liver Fibrosis.
    Hepatology. 2020;72:347-349.
    PubMed    


  74. YANG JD, Mara KC, Gores GJ, Roberts LR, et al
    Reply.
    Hepatology. 2020;72:364-365.
    PubMed    


  75. YANG JD, Mara KC, Gores GJ, Roberts LR, et al
    REPLY.
    Hepatology. 2020;72:362-363.
    PubMed    


  76. LLEO A, Ma X, Gershwin ME, Invernizzi P, et al
    Letter to the Editor: Might Denosumab Fit in Primary Biliary Cholangitis Treatment?
    Hepatology. 2020;72:359-360.
    PubMed    


    June 2020
  77. BANINI BA, Alwatari Y, Stovall M, Ogden N, et al
    Multidisciplinary Management of Hepatic Hydrothorax in 2020: An Evidence-Based Review and Guidance.
    Hepatology. 2020 Jun 25. doi: 10.1002/hep.31434.
    PubMed     Abstract available


  78. CHASCSA DM, Ferre EMN, Hadjiyannis Y, Alao H, et al
    APECED-Associated Hepatitis: Clinical, Biochemical, Histological and Treatment Data from a Large Predominantly American Cohort.
    Hepatology. 2020 Jun 17. doi: 10.1002/hep.31421.
    PubMed     Abstract available


  79. ZHANG J, Li Y, Liu Q, Huang Y, et al
    Sirt6 alleviated liver fibrosis by deacetylating conserved lysine 54 on Smad2 in hepatic stellate cells.
    Hepatology. 2020 Jun 14. doi: 10.1002/hep.31418.
    PubMed     Abstract available


  80. PFEIFFER RM, Rotman Y, O'Brien TR
    Genetic Determinants of Cirrhosis and Hepatocellular Carcinoma Due to Fatty Liver Disease: What's the Score?
    Hepatology. 2020 Jun 7. doi: 10.1002/hep.31413.
    PubMed     Abstract available


  81. KUMAR K, Kulkarni AV
    Sodium-Glucose Cotransporter-2(SGLT2-I) inhibitor are not the magic pills for control of ascites in cirrhosis and diabetes.
    Hepatology. 2020 Jun 3. doi: 10.1002/hep.31399.
    PubMed     Abstract available


  82. PATOULIAS D, Katsimardou A, Papadopoulos C, Doumas M, et al
    Letter to the Editor: Sodium-glucose cotransporter 2 inhibitors (SGLT2-I) ameliorate ascites and peripheral edema in patients with cirrhosis and diabetes.
    Hepatology. 2020 Jun 3. doi: 10.1002/hep.31398.
    PubMed     Abstract available


  83. KARDASHIAN A, Ge J, McCulloch CE, Kappus MR, et al
    Identifying an Optimal Liver Frailty Index Cutoff to Predict Waitlist Mortality in Liver Transplant Candidates.
    Hepatology. 2020 Jun 3. doi: 10.1002/hep.31406.
    PubMed     Abstract available


  84. LUCEY MR, Singal AK
    Integrated Treatment of Alcohol Use Disorder in Patients With Alcohol-Associated Liver Disease: An Evolving Story.
    Hepatology. 2020;71:1891-1893.
    PubMed    


    May 2020
  85. WOLF E, Rich NE, Marrero JA, Parikh N, et al
    Utilization of hepatocellular carcinoma surveillance in patients with cirrhosis: A systematic review and meta-analysis.
    Hepatology. 2020 May 8. doi: 10.1002/hep.31309.
    PubMed     Abstract available


  86. IZZY M, VanWagner LB, Lin G, Altieri M, et al
    Reply.
    Hepatology. 2020;71:1884-1885.
    PubMed    


    April 2020
  87. MAHMUD N, Asrani SK
    Defining (and refining) the role of the Model for End Stage Liver Disease-Lactate (MELD-LA) score in cirrhosis.
    Hepatology. 2020 Apr 20. doi: 10.1002/hep.31287.
    PubMed     Abstract available


  88. MONTALVO-GORDON I, Chi-Cervera LA, Garcia-Tsao G
    Sodium-glucose cotransporter 2 inhibitors (SGLT2-I) ameliorate ascites and peripheral edema in patients with cirrhosis and diabetes.
    Hepatology. 2020 Apr 15. doi: 10.1002/hep.31270.
    PubMed     Abstract available


  89. MELE D, Oliviero B, Mantovani S, Ludovisi S, et al
    Adaptive Natural Killer Cell Functional Recovery in Hepatitis C Virus Cured Patients.
    Hepatology. 2020 Apr 13. doi: 10.1002/hep.31273.
    PubMed     Abstract available


  90. DAVE S, Park S, Murad MH, Barnard A, et al
    Comparative Effectiveness of Entecavir vs Tenofovir for Preventing Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: a Systematic Review and Meta-analysis.
    Hepatology. 2020 Apr 10. doi: 10.1002/hep.31267.
    PubMed     Abstract available


  91. SERPER M, Weinberg EM, Cohen JB, Reese PP, et al
    Mortality and hepatic decompensation in patients with cirrhosis and atrial fibrillation treated with anticoagulation.
    Hepatology. 2020 Apr 8. doi: 10.1002/hep.31264.
    PubMed     Abstract available


  92. PRIMIGNANI M, Tosetti G, Tripodi A
    Thromboelastography guided blood product transfusion in cirrhosis with coagulopathy: real saving or just less waste?
    Hepatology. 2020 Apr 8. doi: 10.1002/hep.31263.
    PubMed     Abstract available


  93. KUMAR A, Sharma P, Arora A
    A new prognostic algorithm based on stage of cirrhosis and HVPG to improve risk-stratification after variceal bleeding.
    Hepatology. 2020 Apr 4. doi: 10.1002/hep.31254.
    PubMed     Abstract available


  94. SEHRAWAT TS, Arab JP, Liu M, Amrollahi P, et al
    Circulating extracellular vesicles carrying sphingolipid cargo for the diagnosis and dynamic risk profiling of alcoholic hepatitis.
    Hepatology. 2020 Apr 4. doi: 10.1002/hep.31256.
    PubMed     Abstract available


  95. RATZIU V
    Timing Is Everything: Improving NASH Histology in Clinical Trials Should Not Be Rushed.
    Hepatology. 2020;71:1146-1149.
    PubMed    


  96. WANG S, Friedman SL
    Taming the Savage Breast From Within: Transcription Factor 21, a Regulator of Stellate Cell Deactivation.
    Hepatology. 2020;71:1150-1153.
    PubMed    


    March 2020
  97. GELLERT-KRISTENSEN H, Richardson TG, Davey Smith G, Nordestgaard BG, et al
    Combined Effect of PNPLA3, TM6SF2, and HSD17B13 Variants on Risk of Cirrhosis and Hepatocellular Carcinoma in the General Population.
    Hepatology. 2020 Mar 19. doi: 10.1002/hep.31238.
    PubMed     Abstract available


  98. LIEBER SR, Heller BJ, Howard CW, Sandler RS, et al
    Complications Associated with Anesthesia Services in Endoscopic Procedures Among Patients with Cirrhosis.
    Hepatology. 2020 Mar 10. doi: 10.1002/hep.31224.
    PubMed     Abstract available


  99. KAMAL H, Westman G, Falconer K, Duberg AS, et al
    Long-term study of hepatitis D infection at secondary care centers: the impact of viremia on liver-related outcomes.
    Hepatology. 2020 Mar 7. doi: 10.1002/hep.31214.
    PubMed     Abstract available


  100. TERKELSEN MK, Bendixen SM, Hansen D, Scott EAH, et al
    Transcriptional dynamics of hepatic sinusoid-associated cells after liver injury.
    Hepatology. 2020 Mar 7. doi: 10.1002/hep.31215.
    PubMed     Abstract available


  101. AZAD AI, Krishnan A, Troop L, Li Y, et al
    Targeted Apoptosis Of Ductular Reactive Cells Reduces Hepatic Fibrosis In A Mouse Model of Cholestasis.
    Hepatology. 2020 Mar 3. doi: 10.1002/hep.31211.
    PubMed     Abstract available


  102. PATEL K, Harrison SA, Elkashab M, Trotter JF, et al
    Cilofexor, a Nonsteroidal FXR Agonist, in Non-Cirrhotic Patients with Nonalcoholic Steatohepatitis: A Phase 2 Randomized Controlled Trial.
    Hepatology. 2020 Mar 1. doi: 10.1002/hep.31205.
    PubMed     Abstract available


  103. WONG GL, Wong VW
    Reply.
    Hepatology. 2020;71:1134.
    PubMed    


  104. LO GH
    Letter to the Editor: Could Variceal Screening Stratified by Liver/Spleen Stiffness Replace the Role of Endoscopy?
    Hepatology. 2020;71:1133.
    PubMed    


  105. UNALP-ARIDA A, Ruhl CE
    Patatin-Like Phospholipase Domain-Containing Protein 3 I148M and Liver Fat and Fibrosis Scores Predict Liver Disease Mortality in the U.S. Population.
    Hepatology. 2020;71:820-834.
    PubMed     Abstract available


  106. AJMERA VH, Liu A, Singh S, Yachoa G, et al
    Clinical Utility of an Increase in Magnetic Resonance Elastography in Predicting Fibrosis Progression in Nonalcoholic Fatty Liver Disease.
    Hepatology. 2020;71:849-860.
    PubMed     Abstract available


  107. DE CHIARA F, Thomsen KL, Habtesion A, Jones H, et al
    Ammonia Scavenging Prevents Progression of Fibrosis in Experimental Nonalcoholic Fatty Liver Disease.
    Hepatology. 2020;71:874-892.
    PubMed     Abstract available


  108. CHANG Y, Ryu S, Kim Y, Cho YK, et al
    Low Levels of Alcohol Consumption, Obesity, and Development of Fatty Liver With and Without Evidence of Advanced Fibrosis.
    Hepatology. 2020;71:861-873.
    PubMed     Abstract available


    February 2020
  109. ZERMATTEN MG, Fraga M, Moradpour D, Bertaggia Calderara D, et al
    Haemostatic alterations in cirrhotic patients: from primary haemostasis to fibrinolysis.
    Hepatology. 2020 Feb 23. doi: 10.1002/hep.31201.
    PubMed     Abstract available


  110. PEERAPHATDIT TB, Nkomo VT, Naksuk N, Simonetto DA, et al
    Long-Term Outcomes After Transcatheter and Surgical Aortic Valve Replacement in Patients With Cirrhosis: A Guide for the Hepatologist.
    Hepatology. 2020 Feb 20. doi: 10.1002/hep.31193.
    PubMed     Abstract available


  111. SHARMA A, Verma AK, Kofron M, Kudira R, et al
    Lipopolysaccharide Reverses Hepatic Stellate Cell Activation via Modulation of cMyb, SMADs and C/EBP Transcription Factors.
    Hepatology. 2020 Feb 16. doi: 10.1002/hep.31188.
    PubMed     Abstract available


  112. DEBES JD, Boonstra A, de Knegt RJ
    NAFLD-Related Hepatocellular Carcinoma and the Four Horsemen of the Apocalypse.
    Hepatology. 2020 Feb 10. doi: 10.1002/hep.31170.
    PubMed     Abstract available


  113. KUMAR S, Verma AK, Rani R, Sharma A, et al
    Hepatic deficiency of augmenter of liver regeneration predisposes to nonalcoholic steatohepatitis and fibrosis.
    Hepatology. 2020 Feb 7. doi: 10.1002/hep.31167.
    PubMed     Abstract available


  114. NATARAJAN Y, Kramer JR, Yu X, Li L, et al
    Risk of Cirrhosis and Hepatocellular Cancer in Patients with Non-Alcoholic Fatty Liver Disease and Normal Liver Enzymes.
    Hepatology. 2020 Feb 5. doi: 10.1002/hep.31157.
    PubMed     Abstract available


  115. RICH NE, John BV, Parikh ND, Rowe I, et al
    Hepatocellular carcinoma demonstrates heterogeneous growth patterns in a multi-center cohort of patients with cirrhosis.
    Hepatology. 2020 Feb 4. doi: 10.1002/hep.31159.
    PubMed     Abstract available


  116. NIEHAUS CE, Strunz B, Cornillet M, Falk CS, et al
    MAIT cells are enriched and highly functional in ascites of patients with decompensated liver cirrhosis.
    Hepatology. 2020 Feb 3. doi: 10.1002/hep.31153.
    PubMed     Abstract available


  117. JOPHLIN LL, Cao S, Shah VH
    The transcriptome of hepatic fibrosis revealed by single cell RNA sequencing.
    Hepatology. 2020 Feb 3. doi: 10.1002/hep.31155.
    PubMed     Abstract available


  118. GUILLOT A, Tacke F
    The Unexpected Role of Neutrophils for Resolving Liver Inflammation by Transmitting MicroRNA-223 to Macrophages.
    Hepatology. 2020;71:749-751.
    PubMed    


  119. PANDEY S
    Letter to the Editor: Re: Noninvasive Tests in Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Critical Insights from STELLAR Trials.
    Hepatology. 2020;71:763-764.
    PubMed    


  120. STERLING RK, King WC, Wahed AS, Kleiner DE, et al
    Evaluating Noninvasive Markers to Identify Advanced Fibrosis by Liver Biopsy in HBV/HIV Co-infected Adults.
    Hepatology. 2020;71:411-421.
    PubMed     Abstract available


  121. SCHUMACHER JD, Kong B, Wu J, Rizzolo D, et al
    Direct and Indirect Effects of Fibroblast Growth Factor (FGF) 15 and FGF19 on Liver Fibrosis Development.
    Hepatology. 2020;71:670-685.
    PubMed     Abstract available


    January 2020
  122. DOS SANTOS MARCON P, de Mattos AZ, Alves de Mattos A
    Letter to the editor: Co-infection of human immunodeficiency virus with hepatitis C virus: a change of paradigm.
    Hepatology. 2020 Jan 21. doi: 10.1002/hep.31123.
    PubMed     Abstract available


  123. LA MURA V, Garcia-Guix M, Berzigotti A, Abraldes JG, et al
    A new prognostic algorithm based on stage of cirrhosis and HVPG to improve risk-stratification after variceal bleeding.
    Hepatology. 2020 Jan 20. doi: 10.1002/hep.31125.
    PubMed     Abstract available


  124. JIANG JX, Fish SR, Tomilov A, Li Y, et al
    Non-phagocytic Activation of NOX2 is Implicated in Progressive Non-alcoholic Steatohepatitis During Aging.
    Hepatology. 2020 Jan 17. doi: 10.1002/hep.31118.
    PubMed     Abstract available


  125. FABRELLAS N, Carol M, Palacio E, Aban M, et al
    Nursing care of patients with cirrhosis.
    Hepatology. 2020 Jan 16. doi: 10.1002/hep.31117.
    PubMed     Abstract available


  126. KOLB JM, Conzen K, Wachs M, Crossno J Jr, et al
    Liver Transplantation for Decompensated Cirrhosis Secondary to Telomerase Reverse Transcriptase (TERT) Mutation.
    Hepatology. 2020 Jan 14. doi: 10.1002/hep.31111.
    PubMed     Abstract available


  127. RATZIU V, Sanyal A, Harrison SA, Wong VW, et al
    Cenicriviroc Treatment for Adults with Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study.
    Hepatology. 2020 Jan 13. doi: 10.1002/hep.31108.
    PubMed     Abstract available


  128. TANTAI X, Liu N, Wang J
    Letter to Editor: The Association Between Diabetes and Hepatocellular carcinoma in Patients With Cirrhosis Caused by Nonalcoholic Fatty Liver Disease.
    Hepatology. 2020 Jan 6. doi: 10.1002/hep.31099.
    PubMed     Abstract available


  129. FENG Z, Rong P, Wang W
    Hepatocellular Carcinoma Risk in Patients With NASH Cirrhosis and Diabetes: Insufficient for Individual Management.
    Hepatology. 2020 Jan 6. doi: 10.1002/hep.31100.
    PubMed     Abstract available


  130. THALHEIMER U
    Letter to the Editor: The Obsolescence of Sclerotherapy.
    Hepatology. 2020;71:393.
    PubMed    


  131. CRABB DW, Im GY, Szabo G, Mellinger JL, et al
    Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases.
    Hepatology. 2020;71:306-333.
    PubMed    


  132. BALOG S, Li Y, Ogawa T, Miki T, et al
    Development of Capsular Fibrosis Beneath the Liver Surface in Humans and Mice.
    Hepatology. 2020;71:291-305.
    PubMed     Abstract available


  133. GELLERT-KRISTENSEN H, Nordestgaard BG, Tybjaerg-Hansen A, Stender S, et al
    High Risk of Fatty Liver Disease Amplifies the Alanine Transaminase-Lowering Effect of a HSD17B13 Variant.
    Hepatology. 2020;71:56-66.
    PubMed     Abstract available


    December 2019
  134. CHANDRAMOULI S, Lee WM, Lo J, Toomay S, et al
    Prophylactic Transjugular Intrahepatic Portosystemic Shunt Placement for Cirrhosis Management in Pregnancy.
    Hepatology. 2019 Dec 21. doi: 10.1002/hep.31081.
    PubMed     Abstract available


  135. GAO E, Cheema H, Waheed N, Mushtaq I, et al
    OSTalpha deficiency: A disorder with cholestasis, liver fibrosis and congenital diarrhea.
    Hepatology. 2019 Dec 21. doi: 10.1002/hep.31087.
    PubMed     Abstract available


  136. KARVAR S, Ansa-Addo EA, Suda J, Singh S, et al
    Moesin, an ERM family member, regulates hepatic fibrosis.
    Hepatology. 2019 Dec 20. doi: 10.1002/hep.31078.
    PubMed     Abstract available


  137. YANG NB, Li GX, Chu JG, Wang YJ, et al
    Letter to the Editors: Consider More Factors When Studying Risk of Cirrhosis and Hepatocellular Cancer in NAFLD Patients.
    Hepatology. 2019 Dec 17. doi: 10.1002/hep.31075.
    PubMed     Abstract available


  138. D'AMICO G, Abraldes JG, Rebora P, Valsecchi MG, et al
    Ordinal Outcomes Are Superior to Binary Outcomes for Designing and Evaluating Clinical Trials in Compensated Cirrhosis.
    Hepatology. 2019 Dec 14. doi: 10.1002/hep.31070.
    PubMed     Abstract available


  139. PROESCHOLD-BELL RJ, Evon DM, Yao J, Niedzwiecki D, et al
    A randomized controlled trial of an integrated alcohol reduction intervention in patients with hepatitis C infection.
    Hepatology. 2019 Dec 5. doi: 10.1002/hep.31058.
    PubMed     Abstract available


    November 2019
  140. ROGAL S, Youk A, Zhang H, Gellad WF, et al
    Impact of Alcohol Use Disorder Treatment on Clinical Outcomes among Patients with Cirrhosis.
    Hepatology. 2019 Nov 23. doi: 10.1002/hep.31042.
    PubMed     Abstract available


  141. KOSHY AN, Farouque O, Calafiore P, Gow PJ, et al
    Diagnosis of Cirrhotic Cardiomyopathy: The Role of an Impaired Cardiac Reserve.
    Hepatology. 2019 Nov 11. doi: 10.1002/hep.31034.
    PubMed     Abstract available


  142. EATON JE, Vuppalanchi R, Reddy R, Sathapathy S, et al
    Liver Injury in Patients with Cholestatic Liver Disease Treated with Obeticholic Acid.
    Hepatology. 2019 Nov 4. doi: 10.1002/hep.31017.
    PubMed     Abstract available


  143. KANWAL F, Kramer J, Li L, Dai J, et al
    Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Non-alcoholic Fatty Liver Disease.
    Hepatology. 2019 Nov 1. doi: 10.1002/hep.31014.
    PubMed     Abstract available


    October 2019
  144. ASRANI SK
    Accurate assessment of renal function in cirrhosis.
    Hepatology. 2019 Oct 25. doi: 10.1002/hep.31006.
    PubMed     Abstract available


  145. STICKEL F, Lutz P, Buch S, Nischalke HD, et al
    Genetic variation in HSD17B13 reduces the risk of developing cirrhosis and hepatocellular carcinoma in alcohol misusers.
    Hepatology. 2019 Oct 19. doi: 10.1002/hep.30996.
    PubMed     Abstract available


  146. HYDE AM, Carbonneau M, Abraldes JG, Tandon P, et al
    Advanced Practice Providers: Raising Our Defenses Against the Rising Tide of Cirrhosis.
    Hepatology. 2019 Oct 12. doi: 10.1002/hep.30987.
    PubMed     Abstract available


  147. LIU F, Goh GB, Tiniakos D, Wee A, et al
    qFIBS: A Novel Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic Steatohepatitis.
    Hepatology. 2019 Oct 10. doi: 10.1002/hep.30986.
    PubMed     Abstract available


  148. POLI E, Kounis I, Guettier C, Verstuyft C, et al
    Post-Liver Transplantation Sinusoidal Obstruction Syndrome With Refractory Ascites Induced by Mycophenolate Mofetil.
    Hepatology. 2019 Oct 9. doi: 10.1002/hep.30984.
    PubMed     Abstract available


    September 2019
  149. LIU Y, Chen K, Li F, Gu Z, et al
    Probiotic LGG prevents liver fibrosis through inhibiting hepatic bile acid synthesis and enhancing bile acid excretion in mice.
    Hepatology. 2019 Sep 30. doi: 10.1002/hep.30975.
    PubMed     Abstract available


  150. KARSDAL MA, Detlefsen S, Daniels SJ, Nielsen MJ, et al
    Is the total amount as important as localization and type of collagen in liver fibrosis due to steatohepatitis?
    Hepatology. 2019 Sep 25. doi: 10.1002/hep.30969.
    PubMed     Abstract available


  151. NAKANO Y, Kamiya A, Sumiyoshi H, Tsuruya K, et al
    A novel deactivation factor of fibrogenic hepatic stellate cells induces regression of liver fibrosis in mice.
    Hepatology. 2019 Sep 24. doi: 10.1002/hep.30965.
    PubMed     Abstract available


  152. KIM YC, Jung H, Seok S, Zhang Y, et al
    MicroRNA-210 promotes bile acid-induced cholestatic liver injury by targeting mixed-lineage leukemia-4 methyltransferase in mice.
    Hepatology. 2019 Sep 24. doi: 10.1002/hep.30966.
    PubMed     Abstract available


  153. DUSZYNSKI CC, Avati V, Lapointe AP, Scholkmann F, et al
    Near infrared spectroscopy reveals brain hypoxia and cerebrovascular dysregulation in primary biliary cholangitis.
    Hepatology. 2019 Sep 19. doi: 10.1002/hep.30920.
    PubMed     Abstract available


  154. ASRANI SK, Jennings LW, Kim WR, Kamath P, et al
    MELD-GRAIL-Na: Glomerular filtration rate and mortality on Liver-Transplant Waiting List.
    Hepatology. 2019 Sep 16. doi: 10.1002/hep.30932.
    PubMed     Abstract available


  155. MOORING M, Fowl BH, Lum SZC, Liu Y, et al
    Hepatocyte Stress Increases Expression of YAP and TAZ in Hepatocytes to Promote Parenchymal Inflammation and Fibrosis.
    Hepatology. 2019 Sep 10. doi: 10.1002/hep.30928.
    PubMed     Abstract available


  156. TARDELLI M, Bruschi FV, Fuchs CD, Claudel T, et al
    Monoacylglycerol lipase inhibition protects from liver injury in mouse models of sclerosing cholangitis.
    Hepatology. 2019 Sep 10. doi: 10.1002/hep.30929.
    PubMed     Abstract available


    August 2019
  157. MATYAS C, Erdelyi K, Trojnar E, Zhao S, et al
    Interplay of liver-heart inflammatory axis and cannabinoid 2 receptor signalling in an experimental model of hepatic cardiomyopathy.
    Hepatology. 2019 Aug 30. doi: 10.1002/hep.30916.
    PubMed     Abstract available


  158. BEUERS U, Hohenester S
    Fatigue in Primary Biliary Cholangitis: no Place for Rituximab.
    Hepatology. 2019 Aug 23. doi: 10.1002/hep.30906.
    PubMed     Abstract available


  159. MOHANTY SK, Lobeck I, Donnelly B, Dupree P, et al
    Rotavirus reassortant induced murine model of liver fibrosis parallels human biliary atresia.
    Hepatology. 2019 Aug 23. doi: 10.1002/hep.30907.
    PubMed     Abstract available


  160. MCCULLOCH K, Romero N, MacLachlan J, Allard N, et al
    Modelling progress towards elimination of hepatitis B in Australia.
    Hepatology. 2019 Aug 16. doi: 10.1002/hep.30899.
    PubMed     Abstract available


    July 2019
  161. KYRITSI K, Chen L, O'Brien A, Francis H, et al
    Modulation of the TPH1/MAO-A/5HT/5HTR2A/2B/2C Axis Regulates Biliary Proliferation and Liver Fibrosis During Cholestasis.
    Hepatology. 2019 Jul 25. doi: 10.1002/hep.30880.
    PubMed     Abstract available


  162. SIMONETTO DA, Kamath PS, Shah VH
    Assessing surgical risk in idiopathic portal hypertension: some answers, an extrapolation, and more questions.
    Hepatology. 2019 Jul 12. doi: 10.1002/hep.30847.
    PubMed     Abstract available


    June 2019
  163. CAREY EJ, Lai JC, Sonnenday C, Tapper EB, et al
    A North American Expert Opinion Statement on Sarcopenia in Liver Transplantation.
    Hepatology. 2019 Jun 20. doi: 10.1002/hep.30828.
    PubMed     Abstract available


  164. WANG Y, Wen H, Fu J, Cai L, et al
    Hepatocyte TRAF6 Aggravates Hepatic Inflammation and Fibrosis by Promoting Lys6- Linked Polyubiquitination of ASK1.
    Hepatology. 2019 Jun 20. doi: 10.1002/hep.30822.
    PubMed     Abstract available


    May 2019
  165. WANG CY, Xiao X, Bayer A, Xu Y, et al
    Ablation of hepatocyte Smad1, Smad5 and Smad8 causes severe tissue iron loading and liver fibrosis in mice.
    Hepatology. 2019 May 24. doi: 10.1002/hep.30780.
    PubMed     Abstract available


  166. GLUCHOWSKI NL, Gabriel KR, Chitraju C, Bronson RT, et al
    Hepatocyte Deletion of Triglyceride-Synthesis Enzyme DGAT2 Reduces Steatosis without Increasing Inflammation or Fibrosis.
    Hepatology. 2019 May 13. doi: 10.1002/hep.30765.
    PubMed     Abstract available


  167. SUTHERLAND N, Li Wai Suen CFD, Mills C, Lokan J, et al
    Fibrosing cholestatic hepatitis-like syndrome in an immunocompetent patient with an acute flare of chronic hepatitis B.
    Hepatology. 2019 May 11. doi: 10.1002/hep.30763.
    PubMed     Abstract available


  168. XIAO Y, Liu R, Li X, Gurley EC, et al
    Long non-coding RNA H19 contributes to cholangiocyte proliferation and cholestatic liver fibrosis in biliary atresia.
    Hepatology. 2019 May 7. doi: 10.1002/hep.30698.
    PubMed     Abstract available


    April 2019
  169. BAJAJ JS, Salzman NH, Acharya C, Sterling RK, et al
    Fecal Microbial Transplant Capsules are Safe in Hepatic Encephalopathy: A Phase 1, Randomized, Placebo-Controlled Trial.
    Hepatology. 2019 Apr 30. doi: 10.1002/hep.30690.
    PubMed     Abstract available


  170. CHEUNG A, Neuschwander-Tetri BA, Kleiner DE, Schabel E, et al
    Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations from the Liver Forum.
    Hepatology. 2019 Apr 29. doi: 10.1002/hep.30672.
    PubMed     Abstract available


  171. DEROSSI C, Bambino K, Morrison J, Sakarin I, et al
    Mannose Phosphate Isomerase and Mannose Regulate Hepatic Stellate Cell Activation and Fibrosis in Zebrafish and Humans.
    Hepatology. 2019 Apr 23. doi: 10.1002/hep.30677.
    PubMed     Abstract available


  172. SANYAL AJ, Harrison SA, Ratziu V, Abdelmalek MF, et al
    The Natural History of Advanced Fibrosis due to Nonalcoholic Steatohepatitis: Data from the Simtuzumab Trials.
    Hepatology. 2019 Apr 16. doi: 10.1002/hep.30664.
    PubMed     Abstract available


  173. LIU R, Li X, Zhu W, Wang Y, et al
    Cholangiocyte-derived exosomal LncRNA H19 promotes hepatic stellate cell activation and cholestatic liver fibrosis.
    Hepatology. 2019 Apr 15. doi: 10.1002/hep.30662.
    PubMed     Abstract available


  174. DESROCHES-CASTAN A, Tillet E, Ricard N, Ouarne M, et al
    BMP9 is a paracrine factor controlling liver sinusoidal endothelial cell fenestration and protecting from hepatic fibrosis.
    Hepatology. 2019 Apr 9. doi: 10.1002/hep.30655.
    PubMed     Abstract available


    March 2019
  175. ELKRIEF L, Ferrusquia-Acosta J, Payance A, Moga L, et al
    Abdominal surgery in patients with idiopathic noncirrhotic portal hypertension: a multicenter retrospective study.
    Hepatology. 2019 Mar 29. doi: 10.1002/hep.30628.
    PubMed     Abstract available


  176. WANG C, Zheng X, Jiang P, Tang R, et al
    Genome Wide Association Studies of Specific Antinuclear Autoantibody Sub-phenotypes in Primary Biliary Cholangitis.
    Hepatology. 2019 Mar 10. doi: 10.1002/hep.30604.
    PubMed     Abstract available


    February 2019
  177. HARRISON SA, Rossi SJ, Paredes AH, Trotter JF, et al
    NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients with Nonalcoholic Steatohepatitis.
    Hepatology. 2019 Feb 25. doi: 10.1002/hep.30590.
    PubMed     Abstract available


    January 2019
  178. PRATT DS
    Hepatology Elsewhere.
    Hepatology. 2019 Jan 23. doi: 10.1002/hep.30517.
    PubMed     Abstract available


  179. HASAN KM, Friedman TC, Shao X, Parveen M, et al
    E-cigarettes and Western Diet: Important Metabolic Risk Factors for Hepatic Diseases.
    Hepatology. 2019 Jan 21. doi: 10.1002/hep.30512.
    PubMed     Abstract available


    December 2018
  180. AGUILAR-BRAVO B, Rodrigo-Torres D, Arino S, Coll M, et al
    Ductular reaction cells display an inflammatory profile and recruit neutrophils in alcoholic hepatitis.
    Hepatology. 2018 Dec 18. doi: 10.1002/hep.30472.
    PubMed     Abstract available


  181. VILAR-GOMEZ E, Vuppalanchi R, Gawrieh S, Ghabril M, et al
    Vitamin E Improves Transplant-free Survival and Hepatic Decompensation among Patients with NASH and Advanced Fibrosis.
    Hepatology. 2018 Dec 1. doi: 10.1002/hep.30368.
    PubMed     Abstract available


    October 2018
  182. FARRELL G, Schattenberg JM, Leclercq I, Yeh MM, et al
    Mouse models of nonalcoholic steatohepatitis Towards optimization of their relevance to human NASH.
    Hepatology. 2018 Oct 29. doi: 10.1002/hep.30333.
    PubMed     Abstract available


  183. PARK H, Wang W, Henry L, Nelson DR, et al
    Impact of all-oral direct-acting antivirals on clinical and economic outcomes in chronic hepatitis C patients in the U.S.
    Hepatology. 2018 Oct 5. doi: 10.1002/hep.30303.
    PubMed     Abstract available


  184. BLANER WS
    Hepatic Stellate Cells (HSCs) and Retinoids: Towards A Much More Defined Relationship.
    Hepatology. 2018 Oct 4. doi: 10.1002/hep.30293.
    PubMed     Abstract available


    September 2018
  185. INZAUGARAT ME, Johnson CD, Holtmann TM, McGeough MD, et al
    NLRP3 inflammasome activation in hepatic stellate cells induces murine liver fibrosis.
    Hepatology. 2018 Sep 4. doi: 10.1002/hep.30252.
    PubMed     Abstract available


    August 2018
  186. LIGAT G, Schuster C, Baumert TF
    HBV core variants, liver fibrosis and hepatocellular carcinoma.
    Hepatology. 2018 Aug 23. doi: 10.1002/hep.30231.
    PubMed     Abstract available


  187. MARETTI-MIRA AC, Wang X, Wang L, DeLeve LD, et al
    Incomplete differentiation of engrafted bone marrow endothelial progenitor cells initiates hepatic fibrosis in the rat.
    Hepatology. 2018 Aug 23. doi: 10.1002/hep.30227.
    PubMed     Abstract available


  188. HLADY RA, Sathyanarayan A, Thompson JJ, Zhou D, et al
    Integrating the Epigenome to Identify Novel Drivers of Hepatocellular Carcinoma.
    Hepatology. 2018 Aug 22. doi: 10.1002/hep.30211.
    PubMed     Abstract available


  189. GORGIS NM, Kennedy C, Lam F, Thompson K, et al
    Clinical Consequences of Cardiomyopathy in Children with Biliary Atresia Requiring Liver Transplantation.
    Hepatology. 2018 Aug 3. doi: 10.1002/hep.30204.
    PubMed     Abstract available


  190. LINDOR KD, Bowlus CL, Boyer J, Levy C, et al
    Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases.
    Hepatology. 2018 Aug 2. doi: 10.1002/hep.30145.
    PubMed     Abstract available


    July 2018
  191. LI W, Li Y, Siraj S, Jin H, et al
    FUNDC1-mediated mitophagy suppresses hepatocarcinogenesis by inhibition of inflammasome activation.
    Hepatology. 2018 Jul 27. doi: 10.1002/hep.30191.
    PubMed     Abstract available


  192. SAYINER M, Golabi P, Stepanova M, Younossi I, et al
    Primary Biliary Cholangitis in Medicare Population: The Impact on Mortality and Resource Utilization.
    Hepatology. 2018 Jul 17. doi: 10.1002/hep.30174.
    PubMed     Abstract available


    May 2018
  193. KHANNA A, Jopson L, Howel D, Bryant A, et al
    Rituximab is Ineffective for Treatment of Fatigue in Primary Biliary Cholangitis: A phase-2 Randomised Controlled Trial.
    Hepatology. 2018 May 23. doi: 10.1002/hep.30099.
    PubMed     Abstract available


    April 2018
  194. PONZIANI FR, Bhoori S, Castelli C, Putignani L, et al
    Hepatocellular Carcinoma is Associated with Gut Microbiota Profile and Inflammation in Non-Alcoholic Fatty Liver Disease.
    Hepatology. 2018 Apr 17. doi: 10.1002/hep.30036.
    PubMed     Abstract available


    March 2018
  195. CAUSSY C, Hsu C, Lo MT, Liu A, et al
    Novel link between gut-microbiome derived metabolite and shared gene-effects with hepatic steatosis and fibrosis in NAFLD.
    Hepatology. 2018 Mar 23. doi: 10.1002/hep.29892.
    PubMed     Abstract available


  196. RAMAMURTHY N, Marchi E, Ansari MA, Pedergnana V, et al
    Impact of IFNL4 genotype on Interferon-stimulated Gene Expression during DAA therapy for Hepatitis C.
    Hepatology. 2018 Mar 13. doi: 10.1002/hep.29877.
    PubMed     Abstract available


    September 2017
  197. LOOMBA R, Lawitz E, Mantry PS, Jayakumar S, et al
    The ASK1 Inhibitor Selonsertib in Patients with Nonalcoholic Steatohepatitis: A Randomized, Phase 2 Trial.
    Hepatology. 2017 Sep 11. doi: 10.1002/hep.29514.
    PubMed     Abstract available


    July 2017
  198. PURI P, Daita K, Joyce A, Mirshahi F, et al
    The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids.
    Hepatology. 2017 Jul 11. doi: 10.1002/hep.29359.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Cirrhosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: